Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5810-2.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody-Dependent Cell Cytotoxicity / immunology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Killer Cells, Natural / immunology
  • Lymphoma, Non-Hodgkin / immunology
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / therapy*
  • Neutrophils / physiology
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab